Home

About Us

Site Map

Search for

Online Learning & Teaching

Webcasts

ESC Slide Resource

World Congress of Cardiology - ESC Congress 2006

ESC Congress 2005 Stockholm

ESC Congress 2004 Munich

ESC Congress 2003 Vienna

Management of CVD Risk in the Perimenopausal Woman 2006

EACPR Leuven Spring Meeting 2005

Heart Failure 2005

ESC Policy Conference on CVD in Women

Education in Heart

Educational Programme Resources

Scientific and Knowledge Search

Clinical Case Portal
Echocardiography

Heart Failure Scientific Reports

CME Calendar

Drospirenone, a new progestin with Aldosterone receptor antagonist activity

Presentation title: Drospirenone, a new progestin with Aldosterone receptor antagonist activity

Author(s): Collins P.

Date: 12 May 2006

[Download complete file]

Click a thumbnail below to view an individual slide:
Drospirenone–a new Progestin with Aldosterone Receptor Antagonist activity		Available hormone preparations
Do progestins have vascular actions, and are they all the same?	Animal: in vivo chronic atheroma development data – MPA	ERT vs. HRT
Human: clinical trial data – MPA – Effects on Blood Pressure	WHI E+PHazard ratios for clinical outcomes	Progestins and cardiovascular diseaseA critical review
PARA effects	When is aldosterone a friend or a foe for the CVS?	Pharmacological and clinical effects of aldosterone and anti-aldosterone action of DRSP
	Systolic blood pressure (SBP) in WHI	Blood pressure in women
Aldosterone - Its Impact On The CVS	Normal Right and Left Ventricle	Hypertrophy of Right Ventricle and Left Ventricle
LVH with Fibrosis	Hypertensive Vessel	Rationale for additional benefits of aldosterone inhibition in patients already on ACE inhibition
	Antimineralocorticoid Activity	Blood Pressure Effects of Drosperinone
Effect of DRSP on BP : Study 305140 - Demographics and baseline characteristics (ITT)	Effect of DRSP on BP : Clinic SBP during 12 weeks post-randomization	Effect of DRSP on BP : Clinic DBP during 12 weeks post-randomization
Effect of DRSP on BP : Ambulatory SBP following 12 weeks of double-blind therapy		Effect of DRSP on BP : Blood pressure in hypertensive subgroup of Angeliq endometrial safety study
Blood pressure and Angeliq®	Effect of DRSP on BP: Dose ranging study in post-menopausal women with stage I and II hypertension
	Blood pressure in women	Summary
Potential cardiovascular benefits - summary

There are no polls available right now.

Site Map | Contact Us | Terms & Conditions | Privacy